Myelodysplastic Syndromes (MDS) News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Onconova stays the course with late-stage study of rigosertib in MDS; shares up 13% - Seeking Alpha



CNA Finance
 
Onconova stays the course with late-stage study of rigosertib in MDS; shares up 13% 
Seeking Alpha
Thinly traded nano cap Onconova Therapeutics (ONTX +12.6%) is up on a healthy 36x surge in volume (although down almost 30% from the intraday high of $2.66) on the heels of its announcement that it will advance the Phase 3 INSPIRE study assessing lead ...
Onconova Therapeutics (ONTX) Says It's Moving Forward with ... StreetInsider.com
Onconova Therapeutics (ONTX) Stock: Gaining On Clinical Update CNA Finance (press release)
Onconova Therapeutics, Inc. (ONTX) Reaches $2.10 After 8.00% Up Move; OXBRIDGE RE HOLDINGS Ltd (OXBR)'s ... San Times

all 12 news articles » 


Curis (CRIS) Reports Initiation of Phase 1 Trial of CA-4948 - StreetInsider.com



Curis (CRIS) Reports Initiation of Phase 1 Trial of CA-4948 
StreetInsider.com
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Curis, Inc. (NASDAQ: CRIS) today announced initiation of patient dosing in a Phase 1 trial of CA-4948, an orally available small molecule ...
Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with ... PR Newswire (press release)

all 2 news articles » 


Myelodysplastic Syndrome (MDS) Treatment Drugs Market Is Expanding At CAGR Of 9.5% From 2017 To 2025 ... - Mobile Computing Today



Mobile Computing Today
 
Myelodysplastic Syndrome (MDS) Treatment Drugs Market Is Expanding At CAGR Of 9.5% From 2017 To 2025 ... 
Mobile Computing Today
Myelodysplastic syndrome (MDS) is group of blood and bone marrow disorders. It is form of cancer involving production of abnormal and immature blood cells. The global myelodysplastic syndrome (MDS) treatment drugs market is segmented on the basis of ...

 


New test predicts whether patients with blood cancer respond to therapy - Medical Xpress



Medical Xpress
 
New test predicts whether patients with blood cancer respond to therapy 
Medical Xpress
The best alternative is the drug azacitidine (AZA), which can improve blood production and decrease the likelihood of MDS progressing into leukemia. "About half of MDS patients will not respond to AZA, with few alternatives for those who fail treatment ...

 


Will 2018 Be Celgene Corporation's Best Year Yet? - Motley Fool



Norman Weekly
 
Will 2018 Be Celgene Corporation's Best Year Yet? 
Motley Fool
Late-stage results from two studies of promising candidate luspatercept in treating myelodysplastic syndromes (MDS) and beta-thalassemia are also expected in mid-2018. In addition, Celgene intends to file for FDA approval of fedratinib in treating ...
Digging Into The Data: Celgene Corporation (NASDAQ:CELG) TopChronicle
Celgene (CELG) Reaches $102.35 After 5.00% Down Move; Realty Income (O)'s Sentiment Is 1.27 Thorold News
Celgene Corporation - CELG - Stock Price Today - Zacks Zacks Investment Research
SEC.gov  -Holdings Channel 
all 222 news articles » 


Combination Checkpoint Therapy Gains Ground in AML and MDS - OncLive



OncLive
 
Combination Checkpoint Therapy Gains Ground in AML and MDS 
OncLive
Preliminary data suggest that PD-1 inhibitors have limited single-agent activity in AML and myelodysplastic syndromes (MDS).3,4 CTLA-4 inhibition may have single-agent activity in AML/MDS, as has been shown in post?stem cell transplant relapsed AML ...

 


Thanks to generous hearts, mom has car to get toddler to cancer appointments - The Tennessean



The Tennessean
 
Thanks to generous hearts, mom has car to get toddler to cancer appointments 
The Tennessean
Skylar was diagnosed last year with MDS (Myelodysplastic syndrome), which is a pre-leukemia condition, and Monosomy 7 (a chromosome disorder). The little girl had a bone marrow transplant in the summer and has follow-up appointments once or twice a ...

 


MEI Pharma (MEIP) Given a $7.00 Price Target at Oppenheimer - The Ledger Gazette



MEI Pharma (MEIP) Given a $7.00 Price Target at Oppenheimer 
The Ledger Gazette
MEI Pharma Inc logo Oppenheimer set a $7.00 price objective on MEI Pharma (NASDAQ:MEIP) in a report published on Monday, January 8th. The firm currently has a buy rating on the stock. Several other brokerages have also recently weighed in on MEIP ...

and more » 


What to know in New Orleans this week (Jan. 9-15, 2018) | I-10 ... - bestofneworleans.com



bestofneworleans.com
 
What to know in New Orleans this week (Jan. 9-15, 2018) | I-10 ... 
bestofneworleans.com
Filmmaker Spike Lee is the Zulu Social Aid & Pleasure Club's honorary celebrity grand marshal for its 2018 Carnival. The krewe rolls on Fat Tuesday morning (Tuesday, Feb. 13). Zulu's coronation ball is Friday, Feb. 9 at the Ernest N. Morial Convention ...

and more » 


Onconova Therapeutics Is Looking to Spearhead the Next Drug Development Wave With Its Ongoing Trial - GuruFocus.com



GuruFocus.com
 
Onconova Therapeutics Is Looking to Spearhead the Next Drug Development Wave With Its Ongoing Trial 
GuruFocus.com
The company is Onconova Therapeutics Inc. (NASDAQ:ONTX), and its target is the Ras oncogene. Currently, Onconova is investigating the safety and efficacy of its lead development asset, a drug called rigosertib, in a target indication of myelodysplastic ...
Analyzing Onconova Therapeutics (ONTX) and Optimer ... Week Herald

all 9 news articles »